Myriad Genetics

When Mike heard "prostate cancer," he feared the worst, remembering how he had lost his father to cancer. However, the Prolaris® test gave him peace of mind by revealing his cancer was low risk and could safely pursue active surveillance, allowing him to avoid surgery or radiation. Learn more: https://brnw.ch/21wKr3y #genetictesting #biomarkers #activesurveillance #prostatecancer

Today we announced the addition of a new Universal Plus Panel to our Foresight Carrier Screen. The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions. “Building on our efforts to advance equitable and accessible prenatal care, our latest panel update reflects Myriad’s commitment to continually growing and innovating to provide genetic insights that can help guide family planning decisions for every parent,” said Dale Muzzey, chief scientific officer, Myriad Genetics. “The genes incorporated into the Universal Plus panel were selected based on guideline recommendations, associated condition severity, condition prevalence, clinical actionability of results, and detection sensitivity.” Read the press release below. #carrierscreening

Today we announced that Genetics in Medicine, an official journal of the ACMG - American College of Medical Genetics and Genomics, published a new study validating RiskScore, Myriad’s breast cancer risk assessment tool integrated into its MyRisk Hereditary Cancer Test. “Comprehensive and equitable personalized breast cancer risk assessment integrates known traditional risk factors, germline-mutation testing, and an all-ancestry PRS. The recently published results from a large, real-world cohort demonstrate the value of this combination, particularly its ability to better elucidate risk for the large majority of women who do not have a pathogenic germline mutation,” said Dale Muzzey, chief scientific officer, Myriad Genetics. “Incorporation of a PRS for all ancestries into a precision medicine tool like MyRisk with RiskScore means more women may be able to benefit from getting finer quantitative resolution of their genetically driven risk of developing breast cancer, and they can then work with their physicians on how to best manage that risk.” Read the press release below.

We’re ready to start the day! Join us at booth #25014 as we kick off the American Society of Clinical Oncology (ASCO) Annual Meeting. Stop by to learn about:
• Myriad's germline and somatic testing that provides a complete picture to guide patient treatment
• Industry’s lowest VUS rates and why that’s important for your patients
• Myriad’s plans for both Precise Liquid and Precise MRD, two products soon to launch and round out the Somatic portion of our portfolio
 
#ASCO24 #MyriadGenetics #cancercare #oncology #genetictesting

Make the most of your experience at #ASCO24 and meet with executive leaders from Myriad. Connect with us at Booth #25014 to discuss the value of genetic and genomic testing, and to hear from our Chief Scientific Officer about our plans for Precise MRD. Schedule time with our team before it’s too late! Connect with us now by visiting https://brnw.ch/21wKliU #MyriadGenetics #cancercare #oncology #genetictesting #genomictesting

#ASCO24 update! Join us as we showcase groundbreaking research and innovation that is influencing the future of cancer care. Learn more about our upcoming sessions via the link below. #ASCO24 #MyriadGenetics #education #innovation #cancercare #oncology #genetictesting

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting begins tomorrow! George W. Daneker, Jr. MD, President and Chief Clinical Officer for Oncology at Myriad, highlights how Myriad is advancing oncology care for all patients in the article below. ⬇ #ASCO24

At Myriad, we believe that all patients should have access to an accurate picture of their breast cancer risk, which is why we validated our breast cancer risk assessment tool MyRisk with RiskScore in 2021 for women of all ancestries. Working with industry leading researchers, we assessed data from more than 275,000 women to validate our enhanced method for assessing polygenic breast cancer risk assessments in women across ancestries. Myriad’s providers have already seen impact that polygenic risk scores can have in helping identify breast cancer earlier; we’re pleased to see more data from others that also say the same. It’s important to support research that helps to address ethnic #disparities in #healthcare to protect #healthequity for all.

Congratulations to our #WomensHealth team for winning the 2024 Excellence Award from Communicator Awards for the “Getting Ahead of Breast Cancer” campaign. This #publichealth educational campaign focused on demystifying genetic testing and understanding personal cancer risk by connecting with OBGYNs about patient misconceptions about breast cancer. With over 3,000 entries received from across the US and around the world, the Communicator Awards is the largest and most competitive awards program honoring creative excellence for communications professionals. Read more about the campaign and check out the full list of winners via the link below. #awards #healthcare #breastcancer #education

The heartbreaking headlines that continue to fill our feed with new #breastcancer stories reveal the importance of #earlydetection. From a recent Myriad Genetics #survey, we learned that nearly half of women survey do not know what breast density is and 50% of women surveyed are unsure if breast density has anything to do with breast cancer risk. With these insights, we applaud women brave enough to tell their story, like Amanda, and elevate the importance of early detection for others. Knowledge is power.